AZN AstraZeneca PLC Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

AZN [NYSE]

AstraZeneca PLC

Healthcare | Drug Manufacturers - General | United Kingdom

statements

Index	-	P/E	104.20	EPS (ttm)	0.52	Insider Own	0.50%	Shs Outstand	2.63B	Perf Week	0.69%
Market Cap	141.46B	Forward P/E	21.72	EPS next Y	2.48	Insider Trans	0.00%	Shs Float	2.60B	Perf Month	0.75%
Income	1.34B	PEG	5.57	EPS next Q	0.46	Inst Own	18.30%	Short Float	0.14%	Perf Quarter	11.35%
Sales	24.38B	P/S	5.80	EPS this Y	-39.70%	Inst Trans	-0.51%	Short Ratio	0.68	Perf Half Y	12.49%
Book/sh	5.00	P/B	10.77	EPS next Y	26.21%	ROA	2.20%	Target Price	52.80	Perf Year	40.43%
Cash/sh	2.37	P/C	22.75	EPS next 5Y	18.70%	ROE	10.80%	52W Range	36.15 - 57.44	Perf YTD	8.04%
Dividend	1.40	P/FCF	-	EPS past 5Y	1.00%	ROI	8.30%	52W High	-6.22%	Beta	0.59
Dividend %	2.60%	Quick Ratio	0.70	Sales past 5Y	-1.70%	Gross Margin	80.10%	52W Low	49.02%	ATR	1.49
Employees	70600	Current Ratio	0.90	Sales Q/Q	3.80%	Oper. Margin	12.00%	RSI (14)	55.90	Volatility	2.50% 2.22%
Optionable	Yes	Debt/Eq	1.39	EPS Q/Q	-70.80%	Profit Margin	5.50%	Rel Volume	0.84	Prev Close	55.00
Shortable	Yes	LT Debt/Eq	1.24	Earnings	Apr 29 BMO	Payout	280.10%	Avg Volume	5.33M	Price	53.87
Recom	1.50	SMA20	-0.26%	SMA50	7.67%	SMA200	13.27%	Volume	4,455,360	Change	-2.05%

Nov-22-19

Initiated

SVB Leerink

Outperform

Oct-25-19

Upgrade

Liberum

Hold → Buy

Apr-02-19

Downgrade

UBS

Neutral → Sell

Feb-05-19

Initiated

Exane BNP Paribas

Outperform

Jan-25-19

Upgrade

Shore Capital

Hold → Buy

Dec-11-18

Resumed

Jefferies

Hold

Oct-09-18

Initiated

Guggenheim

Buy

Aug-16-18

Downgrade

Jefferies

Buy → Hold

Mar-19-18

Upgrade

Jefferies

Hold → Buy

Feb-06-18

Reiterated

Leerink Partners

Mkt Perform

$36 → $38

Feb-05-18

Reiterated

Bernstein

Outperform

$40 → $42

Jan-18-18

Reiterated

Leerink Partners

Mkt Perform

$33 → $36

Dec-29-17

Upgrade

JP Morgan

Neutral → Overweight

Oct-16-17

Upgrade

Credit Suisse

Neutral → Outperform

Sep-25-17

Upgrade

Exane BNP Paribas

Neutral → Outperform

Sep-22-17

Upgrade

Bernstein

Mkt Perform → Outperform

Sep-14-17

Downgrade

Liberum

Buy → Hold

Sep-06-17

Upgrade

Natixis Bleichroeder

Neutral → Buy

Aug-09-17

Upgrade

Investec

Hold → Buy

Jul-28-17

Downgrade

Morgan Stanley

Overweight → Equal-Weight

Jun-04-20 10:37PM	Coronavirus vaccine: AstraZeneca boosts potential supply to 2bn BBC
04:13PM	AstraZeneca to Produce 2 Billion Doses of Its Coronavirus Vaccine Candidate Motley Fool
03:37PM	Coronavirus update: HHS moves to boost coronavirus case tracking; AstraZeneca expands vaccine deals Yahoo Finance
02:42PM	Overlooked Covid-19 Vaccine Runners Up Defended by Wall Street Bloomberg
02:16PM	AstraZeneca Seeks To Make 2 Billion Covid-19 Vaccine Doses With New Supply Deals SmarterAnalyst
11:38AM	Gates Pledges $1.6 Billion for Vaccines. What That Means for Covid-19 and Other Diseases. Barrons.com
11:27AM	AstraZeneca targets 2 billion doses, poor countries with COVID vaccine deals Reuters
10:23AM	Trump Picks 5 Coronavirus Vaccine Candidates Per NYT Report Zacks
10:15AM	AstraZeneca Inks Deal to Develop RMP Inhibitors for Cancer Zacks
08:13AM	The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic Benzinga
07:19AM	AstraZeneca Partners With Accent To Develop Novel Cancer Treatments SmarterAnalyst
02:47AM	Germany forges European virus vaccine alliance - Handelsblatt Reuters
02:10AM	5 Promising Covid-19 Vaccines Now Selected For Trumps Operation Warp Speed SmarterAnalyst
01:28AM	Donors pledge $8.8bn for global vaccination programmes Financial Times
Jun-03-20 06:04PM	U.S. Cases Rise 1.2%; N.Y. Deaths Hit 10-Week Low: Virus Update Bloomberg
03:07PM	NYT: Trump identifies five drugmakers most likely to produce a viable COVID-19 vaccine MarketWatch
01:03PM	Vaccine group plans advance market agreement for COVID-19 vaccines Reuters
11:56AM	Brazil to start testing Oxford vaccine against the coronavirus this month Reuters
07:02AM	Is a COVID-19 Vaccine Supply Glut on the Way? Motley Fool
Jun-02-20 10:53AM	AstraZeneca Ranked Most Inventive, Roche Most Innovative GuruFocus.com
09:43AM	Top Ranked Income Stocks to Buy for June 2nd Zacks
08:00AM	Dont Only Bet on Fast Vaccines, Root for Covid Treatments Bloomberg
Jun-01-20 01:58PM	INSIGHT-Scientists hunt pandemic hotspots in race to test vaccines Reuters
11:49AM	AstraZeneca scores twin drug approvals alongside vaccine progress Reuters Videos
10:03AM	Lilly's Cyramza Gets FDA Approval for First-Line Lung Cancer Zacks
09:20AM	AstraZeneca scores twin drug approvals alongside vaccine progress Reuters
07:50AM	U.S. awards new $628 mln contract to boost output of potential COVID-19 vaccine Reuters
07:00AM	BRILINTA Approved in the US to Reduce the Risk of a First Heart Attack or Stroke in High-Risk Patients with Coronary Artery Disease Business Wire
03:01AM	Oxford Biomedica hires French pharma veteran after signing vaccine deal Reuters
02:15AM	AstraZeneca-Merck Lynparza gets EMA's positive recommendation Reuters
02:00AM	INSIGHT-Scientists hunt pandemic hotspots in race to test vaccines Reuters
May-31-20 05:32PM	Bristol-Myers Deserves Better Than a Single-Digit Multiple GuruFocus.com
May-29-20 04:14PM	AstraZeneca Scored A 'Home Run' With Its Cancer Drug And Shares Popped Investor's Business Daily
12:19PM	AstraZeneca's Blockbuster Lung Cancer Drug Has a Huge Sales Boost Ahead Motley Fool
10:29AM	AstraZeneca Reports Progress With Lung Cancer Drug TheStreet.com
09:37AM	Pharma Stock Roundup: MRK, RHHBY Give Coronavirus Updates,SNY to Sell Stake in REGN Zacks
09:13AM	AstraZeneca Stock Jumps on Strong Cancer Drug Data Barrons.com
08:38AM	The Dow Is Edging Down. Salesforce.com Falls as AstraZeneca Rises. Barrons.com
08:01AM	IMFINZI® (durvalumab) Showed a Sustained Overall Survival Benefit in 1st-Line Extensive-Stage Small Cell Lung Cancer in the Phase III CASPIAN Trial Business Wire
08:01AM	IMFINZI plus tremelimumab Demonstrated Promising Clinical Activity and Tolerability in Patients With Advanced Liver Cancer Business Wire
08:00AM	ENHERTU (fam-trastuzumab deruxtecan-nxki) Significantly Improved Tumor Response Rate and Overall Survival in HER2-positive Metastatic Gastric Cancer in Phase II DESTINY-Gastric01 Trial Business Wire
08:00AM	ENHERTU (fam-trastuzumab deruxtecan-nxki) Demonstrated Meaningful Clinical Activity in Patients With HER2-mutant Non-small Cell Lung Cancer in Interim Analysis of Phase II DESTINY-Lung01 Trial Business Wire
08:00AM	ENHERTU (fam-trastuzumab deruxtecan-nxki) Achieved a Tumor Response Rate of 45.3% in Patients With HER2-Positive Metastatic Colorectal Cancer in Phase II DESTINY-CRC01 Business Wire
06:06AM	European stocks fall on rising U.S.-China tensions MarketWatch
03:31AM	AstraZeneca Unveils Data Behind New Win For Blockbuster Drug Bloomberg
02:00AM	Chi-Med Announces NDA Acceptance in China for Savolitinib in the Treatment of Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations GlobeNewswire
May-28-20 09:05PM	A selection of the FTs biggest stories and best reads every Friday Financial Times
05:00PM	TAGRISSO Demonstrated Unprecedented Patient Benefit in the Adjuvant Treatment of EGFR-Mutated Lung Cancer Business Wire
11:01AM	AstraZeneca says it may consider exposing vaccine trial participants to virus Reuters
10:56AM	Pfizer ties up with glass maker Corning for vial supply Reuters
09:39AM	Oxford BioMedica inks deal to make AstraZeneca's potential COVID-19 vaccine Reuters
12:00AM	The lessons and consequences of a failed megadeal Financial Times
May-27-20 12:31PM	Biotech ETFs Soaring on COVID-19 Vaccine Progress Zacks
12:07PM	Trumps Operation Warp Speed: No way it happens, says infectious disease expert Yahoo Finance
12:00AM	Drug wars: how AstraZeneca overtook GSK in UK pharma Financial Times
May-26-20 11:53AM	Novavax expects COVID-19 vaccine trial results in July Yahoo Finance
10:53AM	The Zacks Analyst Blog Highlights: Bristol-Myers, Roche, AstraZeneca, Merck and Johnson & Johnson Zacks
10:52AM	The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, Sanofi and GlaxoSmithKline Zacks
09:59AM	Novavax and Merck Fuel COVID-19 Vaccine Hopes Investopedia
08:00AM	Stocks & ETFs Beneficiaries of Coronavirus Vaccine Ramp-Up Zacks
May-25-20 02:35AM	How Much is AstraZeneca PLC's (LON:AZN) CEO Getting Paid? Simply Wall St.
May-24-20 02:40PM	The Week Ahead In Biotech: ASCO Presentations In The Spotlight Benzinga
01:39PM	Oxford Professor Lowers Coronavirus Vaccine's Odds of Meeting September Deadline Motley Fool
08:21AM	An 'unprecedented' effort to find a coronavirus vaccine has over 100 horses in the race Yahoo Finance
May-23-20 05:22PM	Project leader: Oxford's COVID-19 vaccine trial has 50% chance of success - Telegraph Reuters
May-22-20 03:49PM	Chinese Covid-19 Vaccine Trial Results Are a Good Sign for J&J and AstraZenecas Efforts Barrons.com
03:44PM	Novavax Hopes to Reverse Past Setbacks With Covid-19 Vaccine GuruFocus.com
11:56AM	INSIGHT-How one Indian company could be world's door to a COVID-19 vaccine Reuters
10:31AM	A Covid-19 Vaccine Could Be Ready Late This Year, Bernstein Analyst Says Barrons.com
09:22AM	The race for a coronavirus treatment is fanning fears of 'vaccine nationalism' Yahoo Finance Video
07:29AM	Goldman Borrows U.K. Slogan Against Virus to Apply to British Stocks Stay Alert, Keep Distance Barrons.com
07:29AM	Everything you need to know about the Oxford University vaccine and other efforts to beat coronavirus MarketWatch
07:00AM	U.S. gives AstraZeneca $1.2 billion to fund Oxford University coronavirus vaccine America would get 300 million doses beginning in October MarketWatch
06:16AM	The race for a coronavirus treatment is fanning fears of 'vaccine nationalism' Yahoo Finance
05:58AM	Human trials of British coronavirus vaccine to reach 10,000 Reuters
05:37AM	Pharma Stock Roundup: FDA Ok's Cancer Drugs for New Use, JNJ Stops US Baby Powder Sales Zacks
02:51AM	Coronavirus Vaccine Race Pushes Up Pharma Giants' Production Zacks
12:43AM	PRESS DIGEST-New York Times business news - May 22 Reuters
May-21-20 07:04PM	U.S. Cases Rise 1.5%; Americans Defer Medical Care: Virus Update Bloomberg
05:01PM	Dow closes down 102 points as energy and tech stocks slump amid rising China tensions MarketWatch
04:49PM	4 Top Stock Trades for Friday: NVDA, LULU, TJX, AZN InvestorPlace
04:22PM	The US just bought 400 million doses of a coronavirus vaccine that may never exist Quartz
04:21PM	AstraZeneca Pops On $1.2 Billion In Funding For Coronavirus Vaccine Investor's Business Daily
03:48PM	Fmr. CDC Official: 'were not cutting any corners' on COVID-19 vaccine development Yahoo Finance Video
03:25PM	Coronavirus latest: Thursday, May 21 Yahoo Finance Video
02:24PM	Clovis Oncology Needs a Savior GuruFocus.com
01:48PM	Coronavirus update: Worldwide count tops 5M as US inches toward reopening; AstraZeneca gets $1B Yahoo Finance
12:55PM	U.S. Raises Ante in Vaccine Race With $1.2 Billion for Astra Bloomberg
12:40PM	UK test and trace system is on course for June 1 - health minister Reuters
11:34AM	What AstraZeneca's $1B funding for Oxford's coronavirus vaccine means for the U.S. Yahoo Finance Video
11:27AM	A Peek Into AstraZeneca's P/E Ratio Benzinga
10:10AM	AstraZeneca Gets $1B From U.S. Government for Coronavirus Vaccine TheStreet.com
09:48AM	AstraZeneca Receives Over $1B In BARDA Funding For Coronavirus Vaccine Benzinga
09:36AM	AstraZeneca gets $1B for Oxford vaccine development Yahoo Finance Video
09:15AM	AstraZeneca Is Caught Up in Delicate Vaccine Politics Bloomberg
07:14AM	Coronavirus Vaccine, Unemployment, Nvidia - 5 Things You Must Know Thursday TheStreet.com
06:08AM	AstraZeneca to make billion COVID vaccine doses if tests succeed Reuters Videos
04:40AM	U.K. to Invest in New Vaccine Manufacturing Factory Bloomberg
04:23AM	AstraZeneca books orders for 400m doses of Oxford vaccine Financial Times
04:22AM	AstraZeneca/Merck's Lynparza Get FDA Nod for Prostate Cancer Zacks

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Tudorza/Eklira, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalen and Synagis for infection diseases; Movantik/Moventig, Seroquel IR/Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ASTRAZENECA PLC	10% Owner	Oct 07	Buy	19.00	425,000	8,075,000	14,650,334	Oct 09 04:53 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience